Metraipolis › archive › dc_2d3504aa28e8

Factors and predictors affecting late external dose rates and isolation period in patients after lutetium-177-labeled DOTA-Tyr3-octreotate treatment for… — Europe PMC PMID:40186742

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40186742
DOI
10.1007/s12149-[numero omesso]-5
License (as archived)
solo-consultazione
Archived
2026-10-08T06:57:19.953Z
SHA-256 of the archived text
d251e955919af8c1667b0ba20651af464634ce39acd9723e2f5ae4a5b1fceca6
Stable URL of this page
https://metraipolis.com/documento/dc_2d3504aa28e8

How to cite

Factors and predictors affecting late external dose rates and isolation period in patients after lutetium-177-labeled DOTA-Tyr3-octreotate treatment for… — Europe PMC PMID:40186742 — Europe PMC (en), https://europepmc.org/article/MED/40186742 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2d3504aa28e8 (Metraipolis archive dc_2d3504aa28e8, sha256 d251e955919af8c1667b0ba20651af464634ce39acd9723e2f5ae4a5b1fceca6)
BibTeX
@misc{dc2d3504aa28e8,
  title = {Factors and predictors affecting late external dose rates and isolation period in patients after lutetium-177-labeled DOTA-Tyr3-octreotate treatment for… — Europe PMC PMID:40186742},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40186742},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2d3504aa28e8; sha256 d251e955919af8c1667b0ba20651af464634ce39acd9723e2f5ae4a5b1fceca6},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40186742. Agents can read the archived copy with the MCP tool read_document.